Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival Celebration Sale - 2019
Stock Report

| More

Sanofi India Ltd announces slump sale and transfer of Ankleshwar manufacturing facility

Posted On: 2019-09-11 11:56:35

The Board of Directors of Sanofi India Limited (the Company) at its meeting held on 10th September 2019 approved a transaction for the slump sale and transfer of the manufacturing facility of the Company at Ankleshwar, Gujarat to Zentiva Private Limited for a consideration of Rs. 2,617 million, subject to customary working capital adjustments. This transaction is subject to approval of the members, which will be initiated by the Company through a postal ballot process and few other conditions as defined under the Business Transfer Agreement.

In 2018, as part of a global transaction between Sanofi Group and Advent International, Advent acquired Zentiva, Sanofi Group's European generics business. Following this transaction, Zentiva continued to source products from the Company (through Sanofi group) for its generics business pursuant to a five-year supply agreement (ending in 2023). In view of this transaction, the commercial part of this business was divested by Sanofi group to Advent, while the manufacturing assets continued to be in the Company.

Having received an offer from Zentiva to acquire its manufacturing facility in Ankleshwar, the Company agreed to explore this opportunity as it was in line with its' broader strategic direction. In particular, (i) it was an opportunity to address the excess and unutilized manufacturing capacity that would have remained at the end of the supply agreement, (ii) it supported the focus on manufacturing Sanofi branded products rather than manufacturing for third parties, and (iii) it would improve asset efficiency ratios.

The Board has also taken into consideration the valuation report issued by Deloitte Touche Tohmatsu India LLP and a fairness opinion on such valuation issued by ICICI Securities Limited.

Given the above and considering that the two companies share similar values and commitment towards serving patients and their employees, the Board of Directors of Sanofi India Limited approved this transaction in the long-term interest of all stakeholders.

After closing of the transaction and receipt of the consideration, the Board will consider the best utilization of the proceeds for business development including distribution to the shareholders in an appropriate manner.

The Ankleshwar manufacturing facility is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and finished pharmaceutical products for distribution / sales across the world. In the financial year ended 31st December 2018, this facility contributed Rs. 8,735 million in the revenue (34% of total revenue of the Company including Rs. 6,226 million of domestic sales that will not be impacted), and Rs. 2,945 million to the net worth (13% of total net worth of the Company). Apart from manufacturing products which are exported to Zentiva, it also makes products which are not part of the divestment. The products for domestic market which are being manufactured at the Ankleshwar manufacturing facility will be moved to another manufacturing facility of the Company and will continue to be in the product portfolio of the Company, while most Zentiva export products that were manufactured at the Goa facility will be transferred to the Ankleshwar site. The Company has made necessary arrangements to handle this transition in a secure manner to ensure that there is no business disruption in the supplies of products which have not been divested. Post this transition, the estimated average annual revenue loss to the Company over a period of the next 4 years (balance of five-year supply agreement mentioned above) is about Rs.4,700 million. The Company plans to mitigate the loss of profit in due course through renewed focus on its core activities and brands.

Shares of Sanofi India Ltd was last trading in BSE at Rs.6271.3 as compared to the previous close of Rs. 6178.75. The total number of shares traded during the day was 209 in over 158 trades.

The stock hit an intraday high of Rs. 6297.85 and intraday low of 6150. The net turnover during the day was Rs. 1301421.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Indiabulls Housing Finance Ltd issues offer to debenture holders of NCDs maturing in November, December for pre-mature redemption

LTI Constant Currency Revenue growth up 11.9% YoY

Patel Integrated Logistics Ltd board approves rights issue

Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

I S T Ltd Board approves Sub-division of equity shares

CRISIL reaffirms long-term rating of Indiabulls Housing Finance Ltd

DIL Limited is now Fermenta Biotech Ltd

Jay Bharat Maruti Ltd Q2 consolidated PAT drops to Rs. 3.76 crore

Larsen & Toubro Infotech Ltd board declares first interim dividend of Rs. 12.50 for FY2019-20

Hero MotoCorp announces 5th edition of The Hero Campus Challenge

ZEE Entertainment posts strong performance in a challenging environment

Shemaroo Entertainment Ltd to raise Rs. 250 crores

Larsen & Toubro Infotech Ltd to acquire PowerupCloud

CARE A+ rating assigned to JMC Projects' NCD issue

Brickwork Ratings assigns credit ratings to Vikas EcoTech Ltd

Shemaroo Entertainment Ltd Q2 FY 2019-20 consolidated net profit at Rs. 19.49 crores

ZEE Entertainment Enterprises Ltd posts consolidate PAT of Rs. 413.23 crores in Q2

Larsen & Toubro Infotech Ltd Q2 consolidated PAT at Rs. 360.1 crore

Cyient Ltd announces Q2 FY2019-20 results

TVS Motor Company's EBITDA increased from 8.6% in Q2 of FY 2018-19 to 8.8% in Q2 of FY 2019-20

Mastek Ltd Q2FY20 Total Income at Rs 252.7 crore

Ind-Ra affirms India Glycols Ltd's long-term rating

AksharChem India Ltd announces shutdown of Vinyl Sulphone plant for repairs and maintenance

FDC Ltd to acquire 'ENTEROPLUS' from GlaxoSmithKline Pharmaceuticals Ltd

Only 17 Percent of Banks have Deployed Digital at Scale - Finds Infosys Finacle and Efma 'Innovation in Retail Banking' Report

Alicon Castalloy signs multi-year Contracts aggregating 810 crore with leading Global OEMs and Tier 1 Suppliers

PTron Launches advanced version of Dual Driver Earphones - Boom 3

SEAMEC PRINCESS on hire with Posh Subsea Pte Limited

Cyient Ltd board recommends interim dividend of Rs. 6 for 2019-20

South Indian Bank Ltd Q2 PAT higher at Rs. 84.48 crore

3I Infotech Ltd reports consolidated PAT of Rs. 13.35 crore in Q2

Automotive Stampings & Assemblies Ltd posts loss of Rs. 1.18 crore in Q2

Mastek Ltd Board approves Dividend of Rs. 3 for 2019-20

Pennar Industries bags orders worth INR 304 Crore

TVS Motor Company Ltd reports consolidated net profit of Rs. 253.57 crores in Q2

Chennai Petroleum Corporation Ltd Q2 loss at Rs. 213.64 crore

FORCE Motors Ltd reports Q2 FY 2019-20 net profit of Rs. 4.21 crore

MASTEK Ltd posts consolidated Q2 net profit of Rs. 24.64 crores

AMAL Ltd reports net profit of Rs. 2.35 crore in Q2 FY 2019-20

PVR Ltd Q2 consolidated PAT soars to Rs. 47.67 crores

Chartered Logistics receives award from JSW Cement

Home Credit India and Karur Vysya Bank tie up for an unique Joint Lending partnership

HCL Technologies selected as one of Volvo Cars' main suppliers for digital transformation and IT Services

NIIT recognised as 'Vocational & Skill Development Training Institute' at Franchise Awards 2019

ICRA reaffirms ratings of International Combustion (India) Limited

Ab Sabka Combo Chalega - McDonald's India (West and South) launches two quirky TVCs to promote their festive offer

Prakash Industries Limited commences commercial production from its 5th Sponge Iron Rotary Kiln

Vodafone Idea extends strategic partnership with TCS to enhance Customer Experience

RAH Infotech forges strategic partnership with Tata Communications for Cloud Offerings

Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019